Orchard Therapeutics plc American Depositary Shares
ORTX
ORTX was delisted on the 23rd of January, 2024.
47 hedge funds and large institutions have $24.7M invested in Orchard Therapeutics plc American Depositary Shares in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 10 closing their positions.
6% less funds holding
Funds holding: 50 → 47 (-3)
18% less capital invested
Capital invested by funds: $30.2M → $24.7M (-$5.56M)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
25% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
CHI Advisors
New York
|
+$1.49M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.26M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$466K |
| 4 |
Renaissance Technologies
New York
|
+$306K |
| 5 |
MIAN
Mariner Independent Advisor Network
Overland Park,
Kansas
|
+$288K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$1.94M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$1.78M |
| 3 |
JP Morgan Chase
New York
|
-$765K |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$368K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$360K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
51
Tower Research Capital (TRC)
New York
| – | -$3.6K | -647 | -90% |
|
52
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1.11K | -200 | -100% |
|
|
CWP
53
Concord Wealth Partners
Abingdon,
Virginia
| – | -$1K | -100 | Closed |
|
|
BHWM
54
Beaird Harris Wealth Management
Dallas,
Texas
| – | +$67 | +12 | New |
|
55
Simplex Trading
Chicago,
Illinois
| – | +$557 | +100 | +115% |
|
ORTX Hedge Fund Activity: Q3 2022 in Review
47 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q3 2022, worth a combined $24.7M — down 18% from $30.2M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ORTX and 8 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 9 added.
The largest buyer was CHI Advisors, adding an estimated $1.49M. The largest seller was Artisan Partners, exiting entirely with an estimated $1.94M sold.
- 47 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q3 2022, down from 50 in Q2 2022.
- Funds reported $24.7M of Orchard Therapeutics plc American Depositary Shares stock for Q3 2022, down 18% quarter-over-quarter.
- 8 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q3 2022 and 10 closed out, a net change of -2 holders.
- The largest Orchard Therapeutics plc American Depositary Shares buyer in Q3 2022 was CHI Advisors, an estimated $1.49M added.
- The largest Orchard Therapeutics plc American Depositary Shares seller in Q3 2022 was Artisan Partners, an estimated $1.94M sold.
Based on aggregated 13F filings for Q3 2022.